Status:
COMPLETED
Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
Lead Sponsor:
University of California, San Diego
Conditions:
Schizophrenia
Schizo Affective Disorder
Eligibility:
All Genders
18-50 years
Phase:
PHASE4
Brief Summary
This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fi...
Eligibility Criteria
Inclusion
- diagnosis of schizophrenia OR schizoaffective-depressed OR healthy subjects
- ages 18-50 for all subjects
- double barrier contraception for all subjects
- not pregnant for all subjects
Exclusion
- DSM-IV Axis I or II Diagnosis for for healthy subjects
- MEM or amantadine for patients
- current substance abuse for all subjects
- current recreational drug use for all subjects
- history of other significant medical illness (e.g. cancer, diabetes, heart disease, HIV, seizures) for all subjects
- open head injury or closed head injury with loss of consciousness \> 1 min for all subjects
- hearing or visual impairment for all subjects
- pregnancy for all subjects
- dementia for all subjects
- mental retardation for all subjects
Key Trial Info
Start Date :
April 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT03860597
Start Date
April 1 2018
End Date
March 31 2021
Last Update
December 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Teaching Facility (CTF-B102) at UCSD Medical Center
San Diego, California, United States, 92103